Patrick Sulzgruber
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (15)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Background Fibroblast growth factor 23 (FGF‐23) is crucial in regulating phosphate and vitamin D metabolism and is moreover associated with an increased cardiovascular risk. The specific objective of this study was to investigate the influence of FGF‐23 on cardiovascular outcomes, including hospitalization for heart failure (HHF), postoperative atrial fibrillation, and cardiovascular death, in an unselected patient population after cardiac surgery. Methods and Results Patients undergoing elective coronary artery bypass graft and/or cardiac valve surgery were prospectively enrolled. FGF‐23 blood plasma concentrations were assessed before surgery. A composite of cardiovascular death/HHF was chosen as primary end point. A total of 451 patients (median age 70 years; 28.8% female) were included in the present analysis and followed over a median of 3.9 years. Individuals with higher FGF‐23 quartiles showed elevated incidence rates of the composite of cardiovascular death/HHF (quartile 1, 7.1%; quartile 2, 8.6%; quartile 3, 15.1%; and quartile 4, 34.3%). After multivariable adjustment, FGF‐23 modeled as a continuous variable (adjusted hazard ratio for a 1‐unit increase in standardized log‐transformed biomarker, 1.82 [95% CI, 1.34–2.46]) as well as using predefined risk groups and quartiles remained independently associated with the risk of cardiovascular death/HHF and the secondary outcomes, including postoperative atrial fibrillation. Reclassification analysis indicated that the addition of FGF‐23 to N‐terminal pro‐B‐type natriuretic peptide provides a significant improvement in risk discrimination (net reclassification improvement at the event rate, 0.58 [95% CI, 0.34–0.81]; P <0.001; integrated discrimination increment, 0.03 [95% CI, 0.01–0.05]; P <0.001). Conclusions FGF‐23 is an independent predictor of cardiovascular death/HHF and postoperative atrial fibrillation in individuals undergoing cardiac surgery. Considering an individualized risk assessment, routine preoperative FGF‐23 evaluation may improve detection of high‐risk patients.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (10)
Elisabetta Cerbai
Professor
Università degli Studi di Napoli Federico II
Claudio Borghi
-
Bernhard Richter
Medical University of Vienna
barbara steinlechner
Assoc.Prof.Priv.Doz..Dr.
Medical University of Vienna
Eva Steinacher
Medical University of Vienna
Christian Hengstenberg
Head of Department
Medical University of Vienna
Niema Kazem
Medical University of Vienna
Michael Holzer
Internist, Emergency Phycician, Intensivist, Researcher, Lecturer
Medical University of Vienna
Robert Strassl
Medical University of Vienna
Christoph Veigl
Medical University of Vienna
Make your next move.
Prepare your application
Review drafts before you send them.